Emerging studies suggest Retatrutide , a dual activator targeting both GLP-1 and another hormone, appears to provide a promising step forward for body loss . Early human trials have indicated considerable reductions in visceral fat , potentially exceeding existing body composition treatments. Despite this, more assessment is required to completely